NO20040307L - Piperidinderivater som NMDA-reseptorantagonister - Google Patents

Piperidinderivater som NMDA-reseptorantagonister

Info

Publication number: NO20040307L
Authority: NO; Norway
Prior art keywords: sub; alkyl; sup; hydrogen; groups
Prior art date: 2001-07-24

Application number

NO20040307A

Other languages

English (en)

Other versions

NO327099B1 (no

Inventor

Eva Kovacsne Bozo

Gyorgy Domany

Jozsef Nagy

Sandor Farkas

Istvan Borza

Csilla Horvath

Gizella Bartane Szalai

Sandor Kolok

Istvan Vago

Attila Bielik

Gyorgyi Ignaczne Szendrei

Gyorgy Keseru

Original Assignee

Richter Gedeon Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-24

Filing date

2004-01-23

Publication date

2004-03-23

2001-07-24 Priority claimed from HU0103055A external-priority patent/HU226978B1/hu

2002-07-10 Priority claimed from HU0202213A external-priority patent/HU225905B1/hu

2004-01-23 Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet

2004-03-23 Publication of NO20040307L publication Critical patent/NO20040307L/no

2009-04-20 Publication of NO327099B1 publication Critical patent/NO327099B1/no

Links

229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
150000003053 piperidines Chemical class 0.000 title 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
125000000623 heterocyclic group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
-1 amino, mercapto Chemical class 0.000 abstract 2
125000002619 bicyclic group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
125000005842 heteroatom Chemical group 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000004419 alkynylene group Chemical group 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000002993 cycloalkylene group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
230000003287 optical effect Effects 0.000 abstract 1
125000004043 oxo group Chemical group O=* 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000464 thioxo group Chemical group S=* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)

NO20040307A 2001-07-24 2004-01-23 Piperidinderivater som NMDA-reseptorantagonister, fremgangsmater for fremstilling av disse, og farmasoytiske preparater inneholdende disse NO327099B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
HU0103055A HU226978B1 (en)	2001-07-24	2001-07-24	New carboxylic acid amide compounds, process for their preparation and pharmaceutical compositions containing them and their use
HU0202213A HU225905B1 (en)	2002-07-10	2002-07-10	Solid-supported parallel synthesis of new carboxylic acid amide derivatives
PCT/HU2002/000071 WO2003010159A1 (en)	2001-07-24	2002-07-23	Piperidine derivatives as nmda receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20040307L true NO20040307L (no)	2004-03-23
NO327099B1 NO327099B1 (no)	2009-04-20

Family

ID=90001553

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040307A NO327099B1 (no)	2001-07-24	2004-01-23	Piperidinderivater som NMDA-reseptorantagonister, fremgangsmater for fremstilling av disse, og farmasoytiske preparater inneholdende disse

Country Status (33)

Country	Link
US (1)	US7435744B2 (no)
EP (1)	EP1409477B1 (no)
JP (1)	JP4322113B2 (no)
KR (1)	KR100890676B1 (no)
CN (1)	CN100413860C (no)
AT (1)	ATE408611T1 (no)
AU (1)	AU2002313566B2 (no)
BG (1)	BG66441B1 (no)
BR (1)	BR0211393A (no)
CA (1)	CA2453383C (no)
CO (1)	CO5560570A2 (no)
CY (1)	CY1109401T1 (no)
CZ (1)	CZ2004233A3 (no)
DE (1)	DE60228969D1 (no)
DK (1)	DK1409477T3 (no)
EA (1)	EA010162B1 (no)
EE (1)	EE05429B1 (no)
ES (1)	ES2312603T3 (no)
HK (1)	HK1063464A1 (no)
HR (1)	HRP20040178B1 (no)
IL (1)	IL159393A (no)
IS (1)	IS7066A (no)
MX (1)	MXPA04000737A (no)
NO (1)	NO327099B1 (no)
NZ (1)	NZ530055A (no)
PL (1)	PL216636B1 (no)
PT (1)	PT1409477E (no)
RS (1)	RS50767B (no)
SI (1)	SI1409477T1 (no)
SK (1)	SK287726B6 (no)
UA (1)	UA77684C2 (no)
WO (1)	WO2003010159A1 (no)
ZA (1)	ZA200400417B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10210779A1 (de) *	2002-03-12	2003-10-09	Merck Patent Gmbh	Cyclische Amide
PA8575901A1 (es) *	2002-07-18	2004-07-20	Pfizer Prod Inc	Derivados de piperidina novedosos
ES2222833B1 (es) *	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
US7749999B2 (en)	2003-09-11	2010-07-06	Itherx Pharmaceuticals, Inc.	Alpha-ketoamides and derivatives thereof
EP1666464A4 (en) *	2003-09-25	2008-12-10	Shionogi & Co	PIPERIDINE DERIVATIVE HAVING ANTAGONIST ACTIVITY OF THE NDMA RECEPTOR
WO2005039564A1 (en) *	2003-10-02	2005-05-06	Vertex Pharmaceuticals Incorporated	Phthalimide compounds useful as protein kinase inhibitors
HUP0401522A2 (en) *	2004-07-29	2006-04-28	Richter Gedeon Vegyeszet	New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HU227000B1 (en) *	2004-07-29	2010-04-28	Richter Gedeon Nyrt	Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
US7935706B2 (en)	2006-02-23	2011-05-03	Shionogi & Co., Ltd.	Nitrogen-containing heterocycle derivatives substituted with cyclic group
HUP0600809A3 (en) *	2006-10-27	2008-09-29	Richter Gedeon Nyrt	New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) *	2006-10-27	2008-09-29	Richter Gedeon Nyrt	New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) *	2006-10-27	2008-09-29	Richter Gedeon Nyrt	New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
EP1918281A1 (en) *	2006-11-02	2008-05-07	Laboratorios del Dr. Esteve S.A.	Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
WO2008055945A1 (en)	2006-11-09	2008-05-15	Probiodrug Ag	3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2091948B1 (en)	2006-11-30	2012-04-18	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
MX2009009234A (es)	2007-03-01	2009-12-01	Probiodrug Ag	Uso nuevo de inhibidores de ciclasa de glutaminilo.
EP2865670B1 (en)	2007-04-18	2017-01-11	Probiodrug AG	Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009025265A1 (ja) *	2007-08-21	2009-02-26	Shionogi & Co., Ltd.	ピペラジン誘導体
DE102007047737A1 (de) *	2007-10-05	2009-04-30	Merck Patent Gmbh	Piperidin- und Piperazinderivate
US20100298299A1 (en) *	2007-10-27	2010-11-25	Istvan Vago	non-peptide derivatives as bradykinin b1 antagonists
CA2730253A1 (en) *	2008-07-08	2010-01-14	Alphonso Higuera	Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
US20100048630A1 (en) *	2008-08-21	2010-02-25	Pradeep Banerjee	Methods for treating cns disorders
EP2330899A1 (en) *	2008-08-21	2011-06-15	Richter Gedeon Nyrt.	Methods for treating neuropathic pain
WO2010068794A2 (en)	2008-12-10	2010-06-17	The General Hospital Corporation	Hif inhibitors and use thereof
HUP0900130A3 (en)	2009-03-03	2012-02-28	Richter Gedeon Nyrt	Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
ES2548913T3 (es)	2009-09-11	2015-10-21	Probiodrug Ag	Derivados heterocíclicos como inhibidores de glutaminil ciclasa
EA201290505A1 (ru)	2009-12-15	2013-01-30	Ньюроп, Инк.	Соединения для лечения неврологических расстройств
IN2012DN06631A (no)	2010-02-16	2015-10-23	Pfizer
ES2586231T3 (es)	2010-03-03	2016-10-13	Probiodrug Ag	Inhibidores de glutaminil ciclasa
AU2011226074B2 (en)	2010-03-10	2015-01-22	Vivoryon Therapeutics N.V.	Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
HUP1000424A2 (en)	2010-08-11	2012-05-02	Richter Gedeon Nyrt	Use of radiprodil in attention deficit hyperactivity disorder
US8530670B2 (en)	2011-03-16	2013-09-10	Probiodrug Ag	Inhibitors
CN107266382B (zh) *	2011-12-27	2020-10-27	拜耳知识产权有限责任公司	作为杀菌剂的杂芳基哌啶和杂芳基哌嗪衍生物
ES2627541T3 (es)	2012-04-20	2017-07-28	Ucb Pharma, S.A.	Métodos para tratar la enfermedad de Parkinson
WO2014127256A1 (en) *	2013-02-18	2014-08-21	The Trustees Of Columbia University In The City Of New York	Kappa opioid receptor selective compounds
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
CA2964276A1 (en)	2014-11-05	2016-05-12	Flexus Biosciences, Inc.	Immunoregulatory agents
CN108271370B (zh) *	2015-09-25	2021-03-19	(由卫生与公众服务部部长代表的)***合众国	作为p2y14受体拮抗剂的***衍生物
DK3461819T3 (da)	2017-09-29	2020-08-10	Probiodrug Ag	Inhibitorer af glutaminylcyklase
IL274868B1 (en)	2017-12-08	2024-02-01	Boehringer Ingelheim Int	History of imidazopyridine and their use as medicine
WO2019115586A1 (en) *	2017-12-12	2019-06-20	Phenex Discovery Verwaltungs-GmbH	Oxalamides as modulators of indoleamine 2,3-dioxygenase
CN112867508B (zh)	2018-10-17	2023-09-15	勃林格殷格翰国际有限公司	4-吡啶基甲基-吗啉衍生物及其作为药物的用途
BR112021004993A2 (pt) *	2018-10-17	2021-06-08	Boehringer Ingelheim International Gmbh	derivados de 4-pirqazin-2-ilmetil-morfolina e o uso dos mesmos com medicamento
JP7093470B2 (ja) *	2018-10-17	2022-06-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	４－ピリミジン－５－イルメチル－モルホリン誘導体および医薬としてのその使用
TW202112378A (zh)	2019-06-04	2021-04-01	德商百靈佳殷格翰國際股份有限公司	嘌呤衍生物及其作為藥物之用途
CN113234036B (zh) *	2021-05-12	2023-07-14	斯莱普泰(上海)生物医药科技有限公司	Nmda受体拮抗剂及其用途
WO2023014956A1 (en)	2021-08-06	2023-02-09	Grin Therapeutics, Inc.	Formulations of radiprodil
CN114163388A (zh) *	2021-12-15	2022-03-11	陕西汉江药业集团股份有限公司	芬苯达唑中的杂质i、杂质ⅱ和杂质ⅲ的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE254999C (no)
US2324123A (en)	1941-07-08	1943-07-13	Eastman Kodak Co	Fog inhibitor for photographic developers
US3260723A (en)	1963-08-27	1966-07-12	Parke Davis & Co	4-phenoxy piperidines; alpha4-phenoxy piperideines
NL6501323A (no)	1965-02-02	1966-08-03
US3632767A (en)	1968-02-12	1972-01-04	Mallinckrodt Chemical Works	Treatment of depression with 4-substituted piperidines
AU639529B2 (en)	1987-03-04	1993-07-29	Higuchi, Yoshinari	Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
WO1990014087A1 (en)	1989-05-17	1990-11-29	Pfizer Inc.	2-piperidino-1-alkanol derivatives as antiischemic agents
FR2672286B1 (fr) *	1991-01-31	1994-11-18	Synthelabo	Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
US5436255A (en)	1992-07-23	1995-07-25	Pfizer Inc.	Method of treating diseases susceptable to treatment by blocking NMDA-receptors
TW281670B (no) *	1993-09-02	1996-07-21	Hoffmann La Roche
ZA9610738B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	Subtype selective nmda receptor ligands and the use thereof
WO1997023202A1 (en)	1995-12-22	1997-07-03	STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON	Subtype-selective nmda receptor ligands and the use thereof
ZA9610745B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en)	1995-12-22	1997-06-27	Warner Lambert Co	2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
TW498067B (en) *	1996-07-19	2002-08-11	Hoffmann La Roche	4-hydroxy-piperidine derivatives
DE19643790A1 (de)	1996-10-30	1998-05-07	Merck Patent Gmbh	Benzoxazol-Derivat
US6048900A (en) *	1998-02-13	2000-04-11	Bayer Corporation	Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
EP0927166A1 (en) *	1997-02-14	1999-07-07	Bayer Corporation	Amides as npy5 receptor antagonists
BR9814867A (pt)	1997-10-24	2000-10-03	Warner Lambert Co	Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
PE20000728A1 (es)	1998-06-26	2000-08-21	Cocensys Inc	Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US6553849B1 (en)	1998-10-28	2003-04-29	Dillon F. Scofield	Electrodynamic particle size analyzer
US6399631B1 (en) *	1999-07-23	2002-06-04	Pfizer Inc.	Carbazole neuropeptide Y5 antagonists
US6432976B1 (en)	1999-10-29	2002-08-13	Merck & Co., Inc.	8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6489477B1 (en)	1999-10-29	2002-12-03	Merck & Co., Inc.	2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6316474B1 (en)	1999-10-29	2001-11-13	Merck & Co., Inc.	2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6369076B1 (en)	1999-10-29	2002-04-09	Merck & Co. Inc.	5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6476041B1 (en)	1999-10-29	2002-11-05	Merck & Co., Inc.	1,4 substituted piperidinyl NMDA/NR2B antagonists
US6291499B1 (en)	1999-10-29	2001-09-18	Merck & Co., Inc.	2-cyclohexyl benzimidazole NMDA/NR2B antagonists
AU1153601A (en)	1999-10-29	2001-05-08	Merck Sharp & Dohme Limited	Method to treat pain utilizing benzimidazole NMDA NR2B antagonists

2002
- 2002-07-23 SI SI200230752T patent/SI1409477T1/sl unknown
- 2002-07-23 NZ NZ530055A patent/NZ530055A/en not_active IP Right Cessation
- 2002-07-23 EP EP02753161A patent/EP1409477B1/en not_active Expired - Lifetime
- 2002-07-23 BR BR0211393-7A patent/BR0211393A/pt not_active IP Right Cessation
- 2002-07-23 IL IL159393A patent/IL159393A/en active IP Right Grant
- 2002-07-23 DE DE60228969T patent/DE60228969D1/de not_active Expired - Lifetime
- 2002-07-23 RS YUP-1039/03A patent/RS50767B/sr unknown
- 2002-07-23 DK DK02753161T patent/DK1409477T3/da active
- 2002-07-23 AT AT02753161T patent/ATE408611T1/de active
- 2002-07-23 KR KR1020047001042A patent/KR100890676B1/ko not_active IP Right Cessation
- 2002-07-23 AU AU2002313566A patent/AU2002313566B2/en not_active Expired
- 2002-07-23 EE EEP200400058A patent/EE05429B1/xx unknown
- 2002-07-23 JP JP2003515518A patent/JP4322113B2/ja not_active Expired - Lifetime
- 2002-07-23 CA CA2453383A patent/CA2453383C/en not_active Expired - Lifetime
- 2002-07-23 CZ CZ2004233A patent/CZ2004233A3/cs unknown
- 2002-07-23 WO PCT/HU2002/000071 patent/WO2003010159A1/en active IP Right Grant
- 2002-07-23 EA EA200400213A patent/EA010162B1/ru not_active IP Right Cessation
- 2002-07-23 PL PL367259A patent/PL216636B1/pl unknown
- 2002-07-23 CN CNB028142349A patent/CN100413860C/zh not_active Expired - Lifetime
- 2002-07-23 MX MXPA04000737A patent/MXPA04000737A/es active IP Right Grant
- 2002-07-23 SK SK102-2004A patent/SK287726B6/sk not_active IP Right Cessation
- 2002-07-23 ES ES02753161T patent/ES2312603T3/es not_active Expired - Lifetime
- 2002-07-23 PT PT02753161T patent/PT1409477E/pt unknown
2003
- 2003-12-05 IS IS7066A patent/IS7066A/is unknown
2004
- 2004-01-20 UA UA2004021342A patent/UA77684C2/uk unknown
- 2004-01-20 ZA ZA2004/00417A patent/ZA200400417B/en unknown
- 2004-01-21 US US10/761,940 patent/US7435744B2/en not_active Expired - Lifetime
- 2004-01-23 NO NO20040307A patent/NO327099B1/no not_active IP Right Cessation
- 2004-02-20 BG BG108592A patent/BG66441B1/bg unknown
- 2004-02-23 CO CO04015496A patent/CO5560570A2/es active IP Right Grant
- 2004-02-23 HR HRP20040178AA patent/HRP20040178B1/hr not_active IP Right Cessation
- 2004-08-17 HK HK04106165.2A patent/HK1063464A1/xx not_active IP Right Cessation
2008
- 2008-12-03 CY CY20081101405T patent/CY1109401T1/el unknown

Also Published As

Publication number	Publication date
NZ530055A (en)	2005-07-29
WO2003010159A8 (en)	2004-02-12
JP2005515968A (ja)	2005-06-02
CA2453383C (en)	2010-04-06
SK1022004A3 (en)	2004-07-07
AU2002313566B8 (en)	2003-02-18
SI1409477T1 (sl)	2009-02-28
EA010162B1 (ru)	2008-06-30
RS50767B (sr)	2010-08-31
EP1409477B1 (en)	2008-09-17
EP1409477A1 (en)	2004-04-21
US20040157886A1 (en)	2004-08-12
PL367259A1 (en)	2005-02-21
CY1109401T1 (el)	2014-07-02
WO2003010159A1 (en)	2003-02-06
CA2453383A1 (en)	2003-02-06
PL216636B1 (pl)	2014-04-30
IL159393A0 (en)	2004-06-01
CN100413860C (zh)	2008-08-27
CO5560570A2 (es)	2005-09-30
CZ2004233A3 (cs)	2004-12-15
HRP20040178A2 (en)	2005-04-30
MXPA04000737A (es)	2004-07-08
AU2002313566B2 (en)	2007-05-24
DK1409477T3 (da)	2008-12-08
IS7066A (is)	2003-12-05
EE200400058A (et)	2004-04-15
DE60228969D1 (no)	2008-10-30
JP4322113B2 (ja)	2009-08-26
BR0211393A (pt)	2004-08-17
PT1409477E (pt)	2008-11-20
SK287726B6 (en)	2011-07-06
EA200400213A1 (ru)	2004-08-26
ES2312603T3 (es)	2009-03-01
KR20040041152A (ko)	2004-05-14
HRP20040178B1 (hr)	2013-05-31
ATE408611T1 (de)	2008-10-15
HK1063464A1 (en)	2004-12-31
KR100890676B1 (ko)	2009-03-26
EE05429B1 (et)	2011-06-15
RS103903A (en)	2007-02-05
UA77684C2 (en)	2007-01-15
IL159393A (en)	2011-01-31
BG108592A (bg)	2005-03-31
NO327099B1 (no)	2009-04-20
BG66441B1 (bg)	2014-08-29
US7435744B2 (en)	2008-10-14
ZA200400417B (en)	2005-07-27
CN1556805A (zh)	2004-12-22

Legal Events

Date	Code	Title	Description
2013-05-21	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: RICHTER GEDEON NYRT, HU
2014-06-23	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: UCB PHARMA SA, BE
2022-08-15	MK1K	Patent expired

Publication	Publication Date	Title
NO20040307L (no)	2004-03-23	Piperidinderivater som NMDA-reseptorantagonister
NO970501L (no)	1997-08-06	Substituerte kinazolinderivater
HRP20080226T3 (en)	2008-06-30	Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
NO20101069L (no)	2001-09-06	Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
EA199901102A1 (ru)	2000-08-28	Производные азетидинилпропилпиперидина, промежуточные соединения и применение в качестве антагонистов тахикинина
NO20013684L (no)	2001-09-28	Substituerte fenetylaminderivater
NZ503912A (en)	2002-09-27	Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
DE69401716D1 (de)	1997-03-20	Imidazo [1,2-a] pyrasin-4-on-derivate welche als ampa und nmda receptor antagonisten dienen
DK0759027T3 (da)	2000-03-27	Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
HUP0302193A2 (hu)	2003-11-28	1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
AUPP150098A0 (en)	1998-02-19	Benzamide derivatives
PT1044186E (pt)	2006-07-31	Composto 2-benzilamino-2-fenil-acetamida substituidos
BR0213731A (pt)	2004-10-19	Compostos de silìcio
ATE270289T1 (de)	2004-07-15	Heteroaryloxypropanolamine als beta3- adrenergischer rezeptor-agonisten
CA2210913A1 (en)	1996-08-08	Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives
DE60213087D1 (de)	2006-08-24	Pyrimidin-derivate als selektive inhibitoren von cox-2
DE59604901D1 (de)	2000-05-11	Carbamoylcarbonsäureamide
EA200400758A1 (ru)	2005-06-30	Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
ATE172454T1 (de)	1998-11-15	Pyridazinon derivate mit pharmazeutischer wirkung
CA2285535A1 (en)	1998-11-12	Benzimidazole derivative for treating allergy-related disease
EA200400470A1 (ru)	2004-08-26	Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
DK1193260T3 (da)	2006-04-10	Phenoxazinanaloger til behandling af amyloidosis
ZA956579B (en)	1997-02-07	Saccharin derivatives.
TW429147B (en)	2001-04-11	Pharmaceutical composition for the treatment of CNS disorders
EA200000116A1 (ru)	2000-08-28	Противогрибковые соединения на основе 2,4,4-тризамещенных-1,3-диоксоланов